Primary source: Medicines and Healthcare products Regulatory Agency
Manufacturers and NHS organizations must classify AVT products based on intended use, with transcription tools not regulated as medical devices, while those supporting diagnosis or treatment must comply with medical device regulations.
This guidance provides critical clarity on the regulatory framework for AVT tools, facilitating safer implementation within the NHS and ensuring that products are appropriately classified for compliance.
PV and device vigilance teams need to review their AVT product portfolios to verify correct classification and ensure adherence to medical device vigilance reporting workflows, especially for those tools classified as medical devices.
Regulatory Intelligence Lead
Quarterly or as relevant changes arise
Manufacturers and NHS organizations must evaluate their AVT products against these classification criteria. If a tool is classified as a medical device, it must comply with medical device vigilance reporting requirements, including adverse incident reporting. PV and device vigilance teams should review their portfolios of digital health tools to ensure correct classification and reporting workflows are in place.
PV and device vigilance teams need to review their AVT product portfolios to verify correct classification and ensure adherence to medical device vigilance reporting workflows, especially for those tools classified as medical devices.
The Medicines and Healthcare products Regulatory Agency (MHRA) has published guidance regarding ambient voice technology (AVT) products used in health settings. This guidance differentiates between AVT products solely for transcription (not regulated) and those for diagnosis, treatment, or prevention (regulated). Manufacturers must evaluate their AVT products accordingly to ensure compliance with medical device vigilance reporting requirements.
What changed: Manufacturers and NHS organizations must classify AVT products based on intended use, with transcription tools not regulated as medical devices, while those supporting diagnosis or treatment must comply with medical device regulations.
Why it matters: This guidance provides critical clarity on the regulatory framework for AVT tools, facilitating safer implementation within the NHS and ensuring that products are appropriately classified for compliance.
Practical implication: PV and device vigilance teams need to review their AVT product portfolios to verify correct classification and ensure adherence to medical device vigilance reporting workflows, especially for those tools classified as medical devices.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
